Sign in
TerminatedPhase 3

Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer

Key facts

Who runs it
University Hospital, Lille
Where
France1 site in 1 countryChoose a country to see its locations
Trial code
Status
Terminated
Phase
Phase 3
People taking part
6 people enrolled
Started
25 Aug 2021
Ended
28 Aug 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Preoperative Chemotherapy
  • Surgery
  • Postoperative chemotherapy
Record updated
23 December 2025
Why it stopped
default inclusion

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (30)Hide the full registry criteria

Who can take part

  • Primary diagnosis of UICC stage IV gastric adenocarcinoma with histological proof of the primary tumour (with HER2 status, PCC histology and MMR status available and SRC histology available on anatomo-pathology reports)
  • Without any form of previous treatment (surgery and / or chemotherapy and / or radiotherapy) for this diagnosis other than local endoscopic treatment. Note : 3. pPatients having received first line chemotherapy for at least 2 months and completing inclusion/exclusion criteria can be included in the study at V2
  • Locally resectable primary tumour and oligometastatic lesion accessible to surgical resection or local ablation procedure
  • Oligometastatic lesion : Retro-Peritoneal Lymph Node Metastases (RPLM) and/or another metastatic lesion on only one organ (solid organ, lymph node or limited localised peritoneal carcinomatosis with PCI < 7) according to the following non-exhaustive list of definitions:; RPLM: para-aortal, intra-aorto-caval, para-pancreatic or mesenteric lymph node(s). Note: in duodenum invading gastric cancer, retro-pancreatic nodes are not regarded as metastatic sites; Other acceptable limited metastatic lesions:; Localized potentially operable peritoneal carcinomatosis: PCI < 7 including uni or bilateral Krukenberg tumors (ovarian metastases); Liver: maximum of 5 metastatic lesions that are potentially resectable; Lung: unilateral involvement, potentially resectable; Uni- or bilateral adrenal gland metastases; Extra-abdominal lymph node metastases such as supraclavicular or cervical lymph node involvement; Localized bone involvement (defined as being within one radiation field) Notes: 1. Patients with more than one metastatic site in only one organ are eligible. 2. In case of doubt for considering whether a metastatic site is limited or not, please submit the case with relevant anonymised information to the medical coordinator of the study for approval. 6. Only one solid organ metastatic site (hepatic, lung, adrenal gland, bone, brain...). Patients with more than one metastatic lesion in only one organ are eligible
  • ECOG performance status 0 or 1
  • Man or women aged ≥ 18 years and ≤ 80 years
  • For surgery and/or chemotherapy, adequate cardiac, respiratory, bone marrow, renal and liver functions according to usual practices standards
  • Ability to understand and complete quality of life questionnaires (EORTC QLQ C30 and QLQ STO 22)
  • Negative pregnancy test (urine or serum) performed prior to start the study in for females of childbearing potential with reproductive potential
  • Male and female patients of child-bearing reproductive potential must agree to us an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after the end of study treatment
  • Patient covered by a government Health Insurance
  • Patient who provides a signed written Inform Consent

Who cannot take part

  • Primary tumor irresectability and/or metastatic lesion not accessible for resection or local ablation procedure or need for multi-visceral resection with expected high complication rate
  • Contraindication to chemotherapy or surgery according to the multidisciplinary team decision
  • Proximal (junctionnal) tumour growth across the Z-line requiring additional trans thoracic oesophageal resectionµ
  • Metastatic disease involving more than one solid organ metastatic site
  • Second uncontrolled malignant tumour
  • Emergency surgery due to bleeding or perforation
  • Severe comorbid conditions that may jeopardize short term outcomes (e.g. cardiac, respiratory, bone marrow, renal or liver insufficiency...)
  • Patients kept in detention and/or under legal protection under psychiatric care and/or interned in a social or psychiatric institution
  • Age > 80 years
  • Other histological subtype than adenocarcinoma
  • ECOG performance status ≥ 2 2,3 or 4
  • Diffuse peritoneal carcinomatosis (PCI ≥ 7) or significant ascites
  • Weight loss ≥ 20% persisting despite appropriate nutritional assistance
  • Dihydropyrimidine dehydrogenase Deficiency (DPD)
  • Women who are pregnant or breastfeeding
  • Patients in emergency situations
  • Adult patient under legal protection or in the incapacity to express his/her consent
  • Patient not covered by a health insurance system

Where is this trial?

It has locations in one country. Choose a country to see its locations.

What happens in this trial

What the trial wants to find out

Surgical resection of the primary tumour and treatment of the metastatic site in oligometastatic stage IV metastatic gastric adenocarcinoma enhances survival and improves quality of life with acceptable postoperative morbidity and mortality in a selected group of operable patients with only one metastatic site that does not progress under chemotherapy.

The 2 groups in the trial

  • continuation of chemotherapyExisting treatment, for comparison

    Patients assigned to arm A will continue to receive the same chemotherapy regimen they received before randomization. Chemotherapy should be restarted between D1 and D30 after randomization. In case of poor tolerance to the induction chemotherapy, alternative chemotherapy regimen might be discussed, according to local standards and national guidelines (www.tncd.org).

    Treatment: Preoperative Chemotherapy and Postoperative chemotherapy

  • surgical removal of the primary tumour and treatment of the metastatic site followed by chemotherapyTreatment being tested

    Patients assigned to arm B will undergo gastrectomy (subtotal or total according to the location of the primary tumour) between D1 and D30 after randomization. Subtotal gastrectomy is recommended if it allows a complete resection of the primary tumour to limit postoperative morbidity in such metastatic situations, based on the results of REGATTA

    Treatment: Surgery and Postoperative chemotherapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer - a Multicenter, Prospective, Open-labeled, Two-armed, Randomized, Controlled Phase III Trial
Record updated
23 December 2025